Cargando…
Diversity and antifungal susceptibility of Norwegian Candida glabrata clinical isolates
BACKGROUND: Increasing numbers of immunocompromised patients have resulted in greater incidence of invasive fungal infections with high mortality. Candida albicans infections dominate, but during the last decade, Candida glabrata has become the second highest cause of candidemia in the United States...
Autores principales: | Andersen, Kari-Mette, Kristoffersen, Anne Karin, Ingebretsen, André, Vikholt, Katharina Johnsen, Örtengren, Ulf Thore, Olsen, Ingar, Enersen, Morten, Gaustad, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Co-Action Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748091/ https://www.ncbi.nlm.nih.gov/pubmed/26861194 http://dx.doi.org/10.3402/jom.v8.29849 |
Ejemplares similares
-
Oral, intestinal, and skin bacteria in ventral hernia mesh implants
por: Langbach, Odd, et al.
Publicado: (2016) -
Candida glabrata susceptibility to antifungals and phagocytosis is modulated by acetate
por: Mota, Sandra, et al.
Publicado: (2015) -
Biguanides enhance antifungal activity against Candida glabrata
por: Xu, Shuying, et al.
Publicado: (2018) -
Effect of Antifungal-Treated Host Macrophages on Candida glabrata
por: Li, Hong-Bin, et al.
Publicado: (2021) -
Catechin potentiates the antifungal effect of miconazole in Candida glabrata
por: Hervay, Nora Tóth, et al.
Publicado: (2023)